By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Janssen-Cilag International NV 

1, rue Camille Desmoulins
TSA 91003
Issy-les-Moulineaux  Cedex  92787  France
Phone: 33-1-5500-4500 Fax: 33-1-5500-2885


SEARCH JOBS


Industry
Biotechnology






Company News
Janssen-Cilag International NV (JNJ) Presents Long Term Phase III Efficacy And Safety Data Of Sirukumab In Rheumatoid Arthritis Patients Who Had An Inadequate Response And/Or Who Were Intolerant To Anti-TNFs 6/14/2017 11:05:51 AM
Janssen-Cilag International NV (JNJ) Release: INVOKANA (Canagliflozin) Significantly Reduces The Combined Risk Of Cardiovascular Death, Myocardial Infarction, And Stroke In The CANVAS Programme 6/13/2017 6:55:45 AM
Janssen-Cilag International NV (JNJ) Release: Abiraterone Acetate Plus Prednisone Provided Significant Clinical Benefit In Patients With High-Risk Metastatic Hormone-Naïve Prostate Cancer (Mhnpc), Improving Overall Survival And Radiographic Progression-Free Survival 6/5/2017 11:33:54 AM
Janssen-Cilag International NV (JNJ) Release: Abiraterone Acetate Provided Significant Clinical Benefit In Patients With High-Risk Metastatic Hormone-Naïve Prostate Cancer (mHNPC), Improving Overall Survival And Radiographic Progression-Free Survival 6/5/2017 8:15:42 AM
Janssen-Cilag International NV (JNJ) Release: Darzalex (Daratumumab) Combination Therapy Improved Clinical Outcomes Regardless Of Cytogenetic Risk For Previously-Treated Patients With Multiple Myeloma 6/5/2017 8:02:46 AM
European Commission (EC) Extends Approval For Janssen-Cilag International NV (JNJ)’s DARZALEX (Daratumumab) To Include Multiple Myeloma Patients Who Have Received At Least One Prior Therapy 4/28/2017 6:21:57 AM
Janssen-Cilag International NV (JNJ) Release: EPREX (Epoetin Alfa) Marketing Authorization Extended To Include Treatment Of Symptomatic Anaemia In Patients With Low Or Intermediate-1-Risk Myelodysplastic Syndromes 3/24/2017 6:09:32 AM
Janssen-Cilag International NV (JNJ) Presents Newly-Published Data On The Use Of ZYTIGA (Abiraterone Acetate) Plus Prednisone In The Real-World, Outside The Clinical Trial Setting1 2/17/2017 6:32:05 AM
Janssen-Cilag International NV (JNJ) Release: European Commission (EC) Approves STELARA (Ustekinumab) For Treatment Of Adults With Moderately To Severely Active Crohn’s Disease 11/11/2016 11:39:24 AM
Janssen-Cilag International NV (JNJ) Release:Treatment Outcome Data From The Prostate Cancer Registry Presented For The First Time At The 2016 European Society For Medical Oncology (ESMO) Congress 10/10/2016 11:45:44 AM
1234567
//-->